As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:
15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 182 182 |
1,112%
1,112%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | 17 17 |
114%
114%
|
|
| EBIT (Operating Income) EBIT | 8.51 8.51 |
107%
107%
|
|
| Net Profit | 21 21 |
118%
118%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Markus Warmuth |
| Employees | 142 |
| Founded | 2019 |
| Website | www.monterosatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


